A first-in-human trial of PRT12396 starts next month.
ApexOnco Front Page
Recent articles
Early data are coming with the KRAS G12D degrader ARV-806.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Pfizer reveals the discontinuation of PF-08046044.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The company might have blown Enliven out of the water.
